Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Feb 13, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, financials, disclosure
TL;DR
Aptose Biosciences filed an 8-K on Feb 13, 2025, covering Reg FD and financials.
AI Summary
On February 13, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc., is incorporated in Canada and has its principal executive offices in Toronto.
Why It Matters
This 8-K filing provides an update on Aptose Biosciences Inc.'s regulatory disclosures and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- February 13, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and to provide financial statements and exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Aptose Biosciences Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 13, 2025.
What was Aptose Biosciences Inc. formerly known as?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-02-13 16:42:36
Filing Documents
- f8k_021325.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-25-000819.txt ( ) — 222KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_021325_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On February 13, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated February 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: February 13, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer